Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.98
$1.56
$1.28
▼
$9.50
$66.59M1.7176,423 shs15,745 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.31
-0.4%		$1.34
$1.17
▼
$1.96
$64.23M0.6353,084 shs21,464 shs
Scilex Holding Company stock logo
SCLX
Scilex
$6.75
+0.1%		$7.56
$4.20
▼
$34.27
$57.14M1.6787,880 shs13,809 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.29
$4.18
$1.11
▼
$19.65
$18.09M0.143,127 shs22 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
+2.86%+13.14%+38.46%+8.20%-58.75%
MediciNova, Inc. stock logo
MNOV
MediciNova
-1.50%-3.68%-4.38%-5.07%+3.15%
Scilex Holding Company stock logo
SCLX
Scilex
-2.32%-2.88%-23.06%+7.15%-67.90%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+6.74%-11.14%+16.29%-76.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.98
$1.56
$1.28
▼
$9.50
$66.59M1.7176,423 shs15,745 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.31
-0.4%		$1.34
$1.17
▼
$1.96
$64.23M0.6353,084 shs21,464 shs
Scilex Holding Company stock logo
SCLX
Scilex
$6.75
+0.1%		$7.56
$4.20
▼
$34.27
$57.14M1.6787,880 shs13,809 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.29
$4.18
$1.11
▼
$19.65
$18.09M0.143,127 shs22 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
+2.86%+13.14%+38.46%+8.20%-58.75%
MediciNova, Inc. stock logo
MNOV
MediciNova
-1.50%-3.68%-4.38%-5.07%+3.15%
Scilex Holding Company stock logo
SCLX
Scilex
-2.32%-2.88%-23.06%+7.15%-67.90%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+6.74%-11.14%+16.29%-76.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
2.00
Hold$12.00506.06% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
2.67
Moderate Buy$8.33538.57% Upside
Scilex Holding Company stock logo
SCLX
Scilex
1.00
SellN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZIVO, MNOV, DWTX, and SCLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/24/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/16/2026
Scilex Holding Company stock logo
SCLX
Scilex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/19/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/A$2.33 per shareN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$410K156.66N/AN/A$0.85 per share1.54
Scilex Holding Company stock logo
SCLX
Scilex
$30.25M1.89N/AN/A($24.94) per share-0.27
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,141.13N/AN/A($0.81) per share-5.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$34.26M-$10.60N/AN/AN/AN/A-108.57%-30.28%N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$12M-$0.23N/AN/AN/A-1,962.98%-27.28%-25.24%N/A
Scilex Holding Company stock logo
SCLX
Scilex
-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.71N/AN/AN/AN/AN/A-2,240.92%9/2/2026 (Estimated)

Latest ZIVO, MNOV, DWTX, and SCLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026Q2 2026
Scilex Holding Company stock logo
SCLX
Scilex
-$0.1813N/AN/AN/A$16.00 millionN/A
8/13/2026Q2 2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.14-$0.34-$0.20-$0.34N/AN/A
8/13/2026Q2 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.0633-$0.05+$0.0133-$0.05$0.08 million$0.46 million
5/20/2026Q1 2026
Scilex Holding Company stock logo
SCLX
Scilex
-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million
5/14/2026Q1 2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.22-$0.15+$0.07-$0.15N/AN/A
5/14/2026Q1 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.06-$0.05+$0.01-$0.05$0.19 million$0.19 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/A
5.86
5.86
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
9.09
9.09
Scilex Holding Company stock logo
SCLX
Scilex
N/A
0.08
0.07
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
9.05%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Scilex Holding Company stock logo
SCLX
Scilex
69.67%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
0.30%
MediciNova, Inc. stock logo
MNOV
MediciNova
14.00%
Scilex Holding Company stock logo
SCLX
Scilex
4.50%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
533.63 million33.53 millionN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.22 million42.33 millionOptionable
Scilex Holding Company stock logo
SCLX
Scilex
808.49 million8.11 millionNo Data
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023
March 18, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/?utm_source=marketbeat&utm_medium=referral
Harmony Biosciences Holdings
March 4, 2024  |  forbes.comhttps://www.forbes.com/companies/harmony-biosciences-holdings/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dogwood Therapeutics stock logo

Dogwood Therapeutics NASDAQ:DWTX

$1.98 0.00 (0.00%)
As of 12:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.30 -0.01 (-0.38%)
As of 12:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Scilex stock logo

Scilex NASDAQ:SCLX

$6.75 +0.01 (+0.13%)
As of 12:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$4.29 0.00 (0.00%)
As of 08/13/2026

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas